As of 14 Oct 2026, Hemab Therapeutics has raised $157M across 1 verified round on record; latest: $157 million Series C led by Sofinnova Partners, announced 27 Oct 2025.
1 source
Sources agree. The release describes the unnamed asset manager and sovereign wealth fund as investors, and lists existing investors alongside the financing participants.
Published by hand (healthcap.eu): "Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the completion of a multifold oversubscribed $157 million Series C financing round.": biggest-rounds completeness (K): hand-checked, the cited page states $157 million
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series C [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $157M | 2025-10-27 | Sofinnova Partners | No recent discussion |
1 source [ VERIFIED ] read against 1 source Sources agree. The release describes the unnamed asset manager and sovereign wealth fund as investors, and lists existing investors alongside the financing participants. Published by hand (healthcap.eu): "Hemab Therapeutics, a clinical-stage biotechnology company developing novel prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders, today announced the completion of a multifold oversubscribed $157 million Series C financing round.": biggest-rounds completeness (K): hand-checked, the cited page states $157 million | ||||